Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Mira Pharmaceuticals, Inc.

NASDAQ: MIRA · Life Sciences · 5 alerts · CIK 1904286

Share price
$0.6310Close, Nov 16
Market cap
$26.5M
Shares outstanding
42.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mira Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:09 PM ET 8-K
Clinical Trial Data

Mira Pharmaceuticals Clinical Trial Data

MIRA Pharmaceuticals announced new pharmacological findings for its investigational oral drug candidate MIRA-55, demonstrating high receptor selectivity for CB2 over opioid and COX receptors. The expanded screening showed a 500-fold separation from opioid receptor interactions, supporting its development as a differentiated non-opioid treatment for inflammatory pain. The company is currently advancing IND-enabling activities with a target submission date in the first half of 2027.

4:02 PM ET 8-K
Clinical Trial Data

Mira Pharmaceuticals Clinical Trial Data

MIRA Pharmaceuticals announced positive proof-of-concept results from an exploratory pilot study of its oral drug candidate SKNY-1 in a mouse model of obesity. The study showed significant weight and fat reduction without significant lean-mass loss or rapid weight regain compared to semaglutide, suggesting a differentiated metabolic mechanism beyond appetite suppression.

“What makes SKNY-1 particularly exciting is that our findings point toward a potentially differentiated metabolic approach, with encouraging signals regarding body composition and weight maintenance following treatment discontinuation. We believe these characteristics could become important advantages as we continue advancing SKNY-1, positioning it as a potentially valuable asset within our pipeline and an opportunity to participate in this significant global market.”

Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals
8:01 AM ET 8-K
Clinical Trial Data

Mira Pharmaceuticals Clinical Trial Data

MIRA Pharmaceuticals announced positive results from a 21-day IND-enabling preclinical proof-of-concept study of MIRA-55 for chronic inflammatory pain. The study showed MIRA-55 significantly reduced pain hypersensitivity with efficacy comparable to Celebrex and no observed tolerance, supporting a planned IND submission in Q1 2027.

8:31 AM ET 8-K
Business Update

Mira Pharmaceuticals Business Update

MIRA Pharmaceuticals has advanced its Ketamir-2 Phase 2a clinical program for chemotherapy-induced peripheral neuropathy (CIPN) toward site initiation following a protocol review by the FDA. The company has incorporated the regulator's feedback and submitted the protocol for Institutional Review Board (IRB) review, with site initiation targeted for the first quarter of 2027.

Counterparty
FDA
4:31 PM ET 8-K
Shareholder Meeting

Mira Pharmaceuticals Shareholder Meeting

MIRA Pharmaceuticals held its 2026 Annual Meeting of Stockholders on September 11, 2026, where shareholders elected five directors to the board. Stockholders also ratified the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.